Anti-cancer nuclear hormone receptor-targeting compounds

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, such as a compound of Formula I:or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, to products containing the same, as well as to methods of their use and preparation.